Modern Chinese Medicine Group Co., Ltd. (HKSE: 1643.HK) AI-Powered Stock Analysis
See how Modern Chinese Medicine Group Co., Ltd. scores across key metrics like financial growth, valuation, and market position on the HKSE, using AI-driven evaluation.
1643.HK●HKSE
HealthcareMedical - Pharmaceuticals
HK$0.81
HK$0.02(2.55%)
Hong Kong Market is Open · 12:58
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerModern Chinese Medicine Group Co., Ltd. (HKSE: 1643.HK) Stock Overall Grade
Modern Chinese Medicine Group Co., Ltd.'s grade for its HKSE listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Modern Chinese Medicine Group Co., Ltd.'s overall HKSE stock rating.
Forecast
C+Score
55/100Financial Growth
CScore
40/100Fundamental Growth
DScore
32/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100Modern Chinese Medicine Group Co., Ltd. (HKSE: 1643.HK) AI-Powered Stock Analysis
On the HKSE, 1643.HK demonstrates Normal performance with an overall Forecast Score of 55/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (32/100, D) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), the HKSE-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.(HKSE: 1643.HK) Component Analysis Explained
Understand the key factors behind each Modern Chinese Medicine Group Co., Ltd. (HKSE: 1643.HK) stock grade, including financials, comparisons, and forecasts.